Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Stock Price Up 4% - What's Next?

Key Points

• Armata Pharmaceuticals stock price increased by 4%, reaching a trading high of $3.50 before closing at $3.41, with trading volume significantly up by 182% from its average.
• GSB Wealth Management acquired 30,000 shares of Armata Pharmaceuticals, marking institutional interest in the stock, with such investors currently holding 3.57% of the company.
• The company specializes in bacteriophage therapeutics for antibiotic-resistant infections, with promising candidates like AP-SA02 for Staphylococcus aureus and AP-PA02 for Pseudomonas aeruginosa.

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - )'s stock price rose 4% during trading on Wednesday . The stock traded as high as $3.50 and last traded at $3.41. Approximately 25,372 shares traded hands during trading, an increase of 182% from the average daily volume of 8,986 shares. The stock had previously closed at $3.28.

Armata Pharmaceuticals Stock Performance

The firm's 50-day simple moving average is $2.84 and its 200 day simple moving average is $2.17. The stock has a market capitalization of $123.54 million, a P/E ratio of -3.31 and a beta of 1.12.

Institutional Investors Weigh In On Armata Pharmaceuticals

A hedge fund recently bought a new stake in Armata Pharmaceuticals stock. GSB Wealth Management LLC bought a new stake in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Free Report) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor bought 30,000 shares of the company's stock, valued at approximately $57,000. GSB Wealth Management LLC owned 0.08% of Armata Pharmaceuticals as of its most recent filing with the SEC. Hedge funds and other institutional investors own 3.57% of the company's stock.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.